Life Sciences

Serving life sciences companies for more than 25 years, Latham & Watkins represents leading and emerging companies in this broad and rapidly evolving industry.

Why Latham

Strategic Counsel

Life sciences companies worldwide rely on Latham’s unique combination of industry knowledge, legal acumen and strategic business expertise. Many of the firm’s lawyers hold advanced scientific degrees and have hands-on experience working in life sciences companies or within the government agencies that regulate the industry.

This deep understanding of the global life sciences industry allows Latham's lawyers to offer superior counsel to clients involved in transactions, investigations, litigation, intellectual property matters and regulatory challenges. They understand the economic, market, regulatory and political climates in which life sciences companies operate and integrate these factors when addressing clients’ legal and business needs.

Client-focused Representation

Latham represents public and private life sciences companies at all stages of development, from start-up and emerging growth to mature public companies, in the following industries:

  • Biofuels
  • Bioinformatics
  • Biotechnology
  • Cosmeceuticals 
  • Diagnostics
  • Drug delivery
  • eHealth
  • Genomics
  • Healthcare
  • Medical devices
  • Nanotechnology
  • Pharmaceuticals
  • Proteomics
  • Therapeutics

In addition, the firm’s lawyers play important roles in the industry, serving as primary outside counsel for the Advanced Medical Technology Association and as primary outside FDA counsel to the Medical Device Manufacturers Association. Latham also is a leader in key life sciences industry organizations including BIO, BayBio and BIOCOM.

Deep Industry Knowledge

Latham lawyers work closely with life sciences clients to address their legal needs and achieve their goals throughout the full life cycle of their companies. The firm also serves as company counsel in a range of areas, including:

Lawyers in this group assist clients in raising capital in:

The firm’s mergers and acquisitions work in the life sciences industry routinely includes:

Latham’s regulatory and enforcement work in the life sciences industry covers:

And its technology transactions have included:

  • Asset acquisitions
  • Commercial contracts and license agreements
  • Commercialization channel and sales agreements
  • Joint ventures
  • Outsourcing
  • R&D agreements
  • Strategic alliances
  • Supply and manufacturing agreements
  • University licensing

 Finally, Latham provides IP counseling and litigation services in areas such as:

Awards & Rankings

   
  • Healthcare & Life Sciences Partner Recognized as Business of Pride Honoree - June 16, 2019
  • Healthcare & Life Sciences Vice Chair Named Technology Law Trailblazer - June 04, 2019
  • Latham Named D.C. General Litigation Department of the Year Finalist - June 02, 2019
  • Two Firm Leaders Named Top Women Lawyers in California - May 08, 2019
  • David Callahan Named Illinois Outstanding Intellectual Property Litigator of the Year - April 10, 2019

Latham has “a best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships.” They offer "a true cross-border life sciences focus," and have "high-powered transactional and IP litigation capabilities."

Chambers USA 2018

Events

FDLI Annual ConferenceWebcast: Recent Developments in Health Care Enforcement

Media Coverage

Business of Pride 2019 Honoree, Stuart KurlanderTechnology Law Trailblazer: Judith HaskoLatham Named D.C. General Litigation Department of the Year Finalist

News

Latham Co-Hosts First Annual Boston Healthcare and Life Sciences SummitHealthcare & Life Sciences Partner Recognized as Business of Pride HonoreeHealthcare & Life Sciences Vice Chair Named Technology Law Trailblazer

Thought Leadership

MHRA Releases No-Deal Brexit Guidance for Life Sciences CompaniesEDPB Clarifies Consent and Other Legal Grounds for Clinical TrialsClinical Trials Under the GDPR: What Should Sponsors Consider?